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Abstract
We present a case of cardiac ischaemia associated with capecitabine chemotherapy. An elderly female
receiving capecitabine chemotherapy developed acute onset severe anterior chest pain associated with
ischaemic changes on ECG. The pain and ECG changes failed to respond to thrombolysis and she
proceeded to coronary angiogram and stenting of a thrombosed right coronary vessel. She inadvertently
recommenced her capecitabine with a further episode of chest pain. On cessation of capecitabine she
had no further episodes of chest pain.
BACKGROUND
5-Fluorouracil (5-FU) is among the most commonly used chemotherapy drugs in oncology practice. It is
used to treat colorectal cancer, upper gastrointestinal cancers, breast cancer and head and neck cancers,
either as a single agent or in combination with other chemotherapy drugs. Capecitabine (Xeloda) is an
oral prodrug of 5-FU and is increasingly replacing infusional and bolus intravenous 5-FU. Capecitabine
is a tablet formulation and is usually self-administered by patients at home. Common toxicities of 5-FU
and capecitabine include diarrhoea, mucositis and myelosuppression. However, an association between
5-FU and cardiac toxicity has also been known for almost 40 years,  but this toxicity is less common
and less well known to general physicians. Cardiac toxicity most commonly manifests as chest pain, but
arrhythmias, myocardial infarction, congestive heart failure, cardiogenic shock and sudden death have
all been reported. Estimates of the overall incidence of 5-FU cardiotoxicity range from 1% to 18%.
Similar cardiac toxicity has also been observed with capecitabine and in one study the incidence was
found to be 6.5%.  Mortality in symptomatic patients may be as high as 30%.  Risk factors for 5-FU
induced cardiotoxicity include pre-existing ischaemic heart disease and older age, although it may occur
in young individuals with no significant past medical history. In symptomatic patients, ECG and
myocardial enzymes may show changes consistent with ischaemia or may be normal. Coronary
angiograms may also be normal. The mechanism of this toxicity is not fully delineated but may involve
coronary artery vasospasm secondary to a cardiotoxic metabolite of 5-FU.  It is essential that
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capecitabine (or 5-FU infusion) is discontinued in those patients with chest pain and is not restarted
without consulting an oncologist.
CASE PRESENTATION
A 65-year-old female with metastatic colorectal cancer was advised to receive six cycles of palliative
combination chemotherapy. She was prescribed three-weekly Cap/Ox chemotherapy (capecitabine
tablets 1000 mg/m  twice daily from days 1 to 14, and oxaliplatin 130 mg/m  iv infusion over 2 h on
day one). She had no significant past medical history and gave no history of cardiac risk factors or pre-
existing ischaemic heart disease. Five days after starting cycle 3, she was admitted to the emergency
department with chest pain. She gave a history of sudden onset left anterior chest pain associated with
autonomic symptoms.
INVESTIGATIONS
A 12-lead ECG demonstrated ST elevation in leads II, III and aVF with ST depression in lead aVL (fig 1
).
DIFFERENTIAL DIAGNOSIS
Ischaemic heart disease presenting with symptomatic angina or myocardial infarct is the most likely
cause of chest pain in this case. Other less common causes include spontaneous pneumothorax,
dissecting aortic aneurysm and gastro-oesophageal disease.
TREATMENT
The chest pain was partially relieved by buccal GTN administered by paramedics. The patient was
thrombolysed in the coronary care unit with 7000 U Tenecteplase and commenced on heparin infusion.
There was no resolution of ST changes after 90 min and she proceeded to coronary angiography, which
demonstrated right coronary artery stenosis with distal thrombus (fig 2). This was treated successfully
with coronary artery stenting (fig 3).
OUTCOME AND FOLLOW-UP
The patient was discharged 4 days later with no further chest pain. Inadvertently, she continued to take
capecitabine, despite it being implicated in her infarct. She developed further chest pain, requiring re-
admission to hospital. Her capecitabine was discontinued and she has had no further chest pain. She is
being considered for non-5-FU based chemotherapy.
DISCUSSION
5-FU based chemotherapy is well recognised by oncologists as having the potential to induce
cardiotoxicity. As the above case demonstrates, this toxicity may manifest in those with no recognised
cardiac risk factors or significant past medical history. In the presented case, cardiotoxicity manifested
as infarct associated with coronary artery thrombus, requiring coronary artery stenting. However, a
spectrum of cardiovascular toxicities is associated with capecitabine/5-FU. These include exertional
ischaemic chest pain with potentially normal ECG and normal angiographic findings. This spectrum of
effects reflects observations that 5-FU or its metabolites may induce coronary artery spasm or induce
direct damage to endothelial cells with resulting thrombus formation.  Although organoplatinum drugs
have been implicated in arterial thrombus formation,  oxaliplatin is unlikely to be implicated in this
case. The chest pain recurred on re-challenge with capecitabine making capecitabine (5-FU) the most
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likely cause.
There is no unequivocally effective prophylaxis or treatment for patients who develop 5-FU induced
chest pain, although calcium channel blockers, nitric oxide donors and 5-FU dose reduction have
anecdotally been reported as reducing or preventing symptoms in some patients.  Symptoms are
usually reversible following discontinuation of 5-FU although mortality can be as high as 30%.  It is
now becoming apparent that capecitabine can also cause cardiac toxicity, with an incidence of almost
7%.  Approximately 6200 patients are currently receiving capecitabine each month in the UK for
colorectal cancer and breast cancer (personal communication with Roche Products Ltd, UK, January
2007), and this figure is likely to increase. Patients who develop chest pain are likely to present to
emergency services and therefore all health professionals need to be aware of this potential drug
induced toxicity. In patients receiving 5-FU (or taking oral 5-FU prodrugs such as capecitabine) who
present with suspected cardiac chest pain, it is essential that these drugs are stopped immediately,
cardiac investigations are performed, the patient is advised not to re-start their chemotherapy tablets
and the oncology team is informed promptly.
Acknowledgments
We thank Professor David Newby, consultant cardiologist, University of Edinburgh for the kind
permission to use ECG and angiographic images. We are grateful to Dr Lesley Dawson, consultant
medical oncologist, Edinburgh Cancer Centre, Western General Hospital, Edinburgh for patient
information relating to the case. Thanks to Professor Duncan Jodrell, consultant medical oncologist,
and to Professor David Webb, consultant clinical pharmacologist, both University of Edinburgh, for
advice and comment. We acknowledge the KIS Memorial Colorectal Cancer Fund for financial support
in preparing this article.
Footnotes
Competing interests: none.
Patient consent: Patient/guardian consent was obtained for publication.
REFERENCES
1. Gaveau T, Bauzet P, Marneffe H, et al. Traubles cardiovasculares au cours d’infusions d’anti-
mitotiques a fortes doses: 30 observations cliniques. Anesth Analg Reanim 1969; 26: 311–27.
2. Dent RG, McColl I. 5-Fluorouracil and angina. Lancet 1975; 1: 347–8. [PubMed: 46502]
3. Becker K, Erckenbrecht JF, Haussinger D, et al. Cardiotoxicity of the antiproliferative compound
fluorouracil. Drugs 1999; 57: 475–84. [PubMed: 10235688]
4. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with
capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer
(CRC). Eur J Cancer 2005; 41: 1542–6. [PubMed: 15978800]
LEARNING POINTS
Chest pain may be associated with medications including capecitabine/5-FU.
A full drug history is essential.
Capecitabine treatment should be stopped immediately on developing chest pain and only
restarted after discussion with an oncologist.
10
5
4
Unexpected outcome (positive or negative) including adverse drug reactions: Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing isc...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028446/[17/08/2013 11:52:23]
5. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high dose continuous infusion
fluouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795–1801. [PubMed: 1403060]
6. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529–42.
[PubMed: 1411651]
7. Malet-Martino MC, Gilard V, Desmoulin F, et al. Fluorine nuclear magnetic resonance spectroscopy
of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine
drugs. Clin Chim Acta 2006; 366: 61–73. [PubMed: 16337167]
8. Kinhult S, Albertsson M, Eskilsson J, et al. Antithrombotic treatment in protection against
thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation.
Scanning 2001; 23: 1–8. [PubMed: 11272331]
9. Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and
etoposide. Pharmacotherapy 2002; 22: 1200–4. [PubMed: 12222560]
10. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or
capecitabine. Cancer Chemother Pharmacol 2006; 58: 487–93. [PubMed: 16418875]
Figures and Tables
Figure 1
A 12-lead ECG demonstrating ST elevation in leads II, III and aVF with ST depression in lead aVL.
Figure 2
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Coronary angiogram showing right coronary artery stenosis with distal thrombus.
Figure 3
Coronary angiogram after angioplasty, demonstrating deployed stent and restoration of blood flow in right coronary
vessels.
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